BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK5926371 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK5926371\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07371468-5638@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:GSK5926371: Phase 1 readout est. (NCT07371468)
DESCRIPTION:GSK5926371\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A 
 Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumati
 c Diseases (ARD)\nEstimated primary completion: 15 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gsk5926371#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07371468
URL:https://assetmemo.bio/drug/gsk5926371#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07607925-5638@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20300110
DTEND;VALUE=DATE:20300111
SUMMARY:GSK5926371: Phase 1/2 readout est. (NCT07607925)
DESCRIPTION:GSK5926371\, phase 1/2.\nStudy: A Study to Evaluate Safety and 
 Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Ref
 ractory B-NHL\nEstimated primary completion: 10 January 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gsk5926371#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07607925
URL:https://assetmemo.bio/drug/gsk5926371#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
